| 60.53 0.99 (1.66%) | 02-13 09:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 77.98 |
1-year : | 84.28 |
| Resists | First : | 66.76 |
Second : | 72.16 |
| Pivot price | 65.47 |
|||
| Supports | First : | 58.04 |
Second : | 48.28 |
| MAs | MA(5) : | 64.01 |
MA(20) : | 66.56 |
| MA(100) : | 61.68  |
MA(250) : | 56.96 |
|
| MACD | MACD : | -0.3 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 19.6 |
D(3) : | 28.4 |
| RSI | RSI(14): 36.2 |
|||
| 52-week | High : | 72.16 | Low : | 45.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TECH ] has closed below the lower bollinger band by 15.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 5.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 63.55 - 63.99 | 63.99 - 64.34 |
| Low: | 56.95 - 57.52 | 57.52 - 57.95 |
| Close: | 58.75 - 59.52 | 59.52 - 60.12 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Fri, 13 Feb 2026
Principal Financial Group Inc. Sells 35,059 Shares of Bio-Techne Corp $TECH - MarketBeat
Thu, 12 Feb 2026
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings - simplywall.st
Wed, 11 Feb 2026
5 Insightful Analyst Questions From Bio-Techne's Q4 Earnings Call - Finviz
Wed, 11 Feb 2026
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings - Yahoo Finance
Wed, 11 Feb 2026
What Are Wall Street Analysts' Target Price for Bio-Techne Stock? - FinancialContent
Wed, 11 Feb 2026
Bio-Techne Announces Changes to its Leadership Team - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 156 (M) |
| Shares Float | 154 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 109.9 (%) |
| Shares Short | 10,360 (K) |
| Shares Short P.Month | 9,410 (K) |
| EPS | 0.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.61 |
| Profit Margin | 6.4 % |
| Operating Margin | 16.8 % |
| Return on Assets (ttm) | 6.2 % |
| Return on Equity (ttm) | 3.7 % |
| Qtrly Rev. Growth | -1 % |
| Gross Profit (p.s.) | 5.21 |
| Sales Per Share | 7.83 |
| EBITDA (p.s.) | 2.08 |
| Qtrly Earnings Growth | 14.3 % |
| Operating Cash Flow | 251 (M) |
| Levered Free Cash Flow | 279 (M) |
| PE Ratio | 121.51 |
| PEG Ratio | 0 |
| Price to Book value | 4.71 |
| Price to Sales | 7.6 |
| Price to Cash Flow | 36.92 |
| Dividend | 0.07 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|